Euroespes

Euroespes Receivables

The Accounts Receivable of Euroespes (EEP.MC) as of Nov 15, 2026 is 263,700.00 EUR. In the previous year, Accounts Receivable was 473,000.00 EUR — a change of -44.25% (lower).

Receivables

263,700.00EUR

YoY

-44.25%

Last updated:

Accounts Receivable of Euroespes is 2023 263,700.00 EUR. Accounts Receivable of Euroespes was 2022 473,000.00 EUR. It decreases by -44.25% lower compared to the previous year.

The Euroespes Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2016
550,400.00 EUR
Jan 1, 2017
316,900.00 EUR
Jan 1, 2018
185,500.00 EUR
Jan 1, 2019
189,300.00 EUR
Jan 1, 2020
195,700.00 EUR
Jan 1, 2021
391,000.00 EUR
Jan 1, 2022
473,000.00 EUR
Jan 1, 2023
263,700.00 EUR
The Euroespes Receivables history
YEARReceivablesYoY
263,700.00EUR-44.25%
473,000.00EUR+20.97%
391,000.00EUR+99.80%
195,700.00EUR+3.38%
189,300.00EUR+2.05%
185,500.00EUR-41.46%
316,900.00EUR-42.42%
550,400.00EUR+50.63%
365,400.00EUR+52.25%
240,000.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Euroespes Stock analysis

What does Euroespes do? EuroEspes SA generates revenue through its medical center offering personalized treatment plans, genomic medicine, epigenetics, neuropsychology, neuro-ophthalmology, digital diagnosis, diagnostic imaging, clinical analysis, and nursing services. The company also provides pharmacogenetics services and the Human Identification Genetics card, which identifies DNA profiles. Its subsidiaries, Euroespes Biotecnologia SA, Distribuidora de Productos SL, and Ebiotec Pharma SL, support these services. The primary customers are individuals seeking prevention, diagnosis, and treatment for central nervous system disorders like Alzheimer and Parkinson, as well as those requiring genomic and DNA-related health solutions. The firm's revenue streams include medical services for neurological conditions, genetic profiling through the Human Identification Genetics card, and specialized pharmacogenetics. These services target patients with chronic neurological diseases and those interested in personalized medicine. The subsidiaries facilitate the delivery of these offerings across biomedical services and pharmaceutical products. EuroEspes SA's business model centers on providing comprehensive care for central nervous system disorders, combining traditional medical approaches with advanced genetic and digital diagnostics. The company focuses on high-value services such as genomic medicine and DNA identification, which appeal to patients seeking tailored healthcare solutions for complex conditions. Euroespes is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Euroespes stock

Accounts Receivable of Euroespes is 263,700.00 EUR in 2023.

Accounts Receivable of Euroespes changed from 473,000.00 EUR to 263,700.00 EUR, representing a -44.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Euroespes since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Euroespes historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Euroespes

All Key Metrics — Euroespes